The study focuses on patients unlikely to benefit from azacitidine/venetoclax or showing early resistance. ・SLS009 showed ...
Stocktwits on MSN
SLS stock rallies ahead of AML trial readout — 'Pharma Bro' Martin Shkreli says he's still 'very bearish,' predicts drug will fail
The debate centers on Sellas’ Phase 3 Regal trial, which is testing its immunotherapy Galinpepimut-S (GPS) as a maintenance ...
Detailed price information for Sellas Life Sciences Group Inc (SLS-Q) from The Globe and Mail including charting and trades.
SELLAS Life Sciences Group Inc. SLS has surged over 200% over the last six months, with a year-to-date stock jump of around ...
SELLAS Life Sciences Group (SLS) is back in focus after encouraging clinical updates on its leukemia programs, including Phase 2 data for SLS009 and ongoing progress in the Phase 3 REGAL trial for ...
Sellas Life Sciences Group Inc. (NASDAQ:SLS) is one of the top long-term biotechnology stocks to buy. On October 27, SELLAS Life Sciences (NASDAQ:SLS) announced the immediate exercise of warrants for ...
We came across a bullish thesis on Sellas Life Sciences Group Inc (SLS) on ValueInvestorsClub by ContraMundem. In this article we will summarize the bulls’ thesis on SLS. Sellas Life Sciences shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results